Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
about
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection.Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation.Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cellsPhase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax.Antibody responses to Cryptococcus neoformans in Indian patients with cryptococcosis.Catecholamine oxidative products, but not melanin, are produced by Cryptococcus neoformans during neuropathogenesis in mice.Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune miceBoth Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3Pathogenesis of pulmonary Cryptococcus neoformans infection in the ratEvaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.Role of sphingosine-1-phosphate (S1P) and S1P receptor 2 in the phagocytosis of Cryptococcus neoformans by alveolar macrophagesAntibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophagesAntibody response that protects against disseminated candidiasisCryptococcus neoformans melanin and virulence: mechanism of actionVariable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.Antibody immunity and invasive fungal infectionsOpsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodiesEosinophil-Cryptococcus neoformans interactions in vivo and in vitro.Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis.The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response.An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding.Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cellImmunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.Relative Contributions of Prenylation and Postprenylation Processing in Cryptococcus neoformans Pathogenesis.Restricted substrate specificity for the geranylgeranyltransferase-I enzyme in Cryptococcus neoformans: implications for virulence.The capsule of the fungal pathogen Cryptococcus neoformans.The use of chitosan to damage Cryptococcus neoformans biofilms.Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responsesHuman antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth.
P2860
Q30424017-A3F52362-A8B2-4A06-AC55-27A80448609BQ33598508-186586CC-8336-42FF-826A-841B5CC47840Q33693515-551149F8-71C6-404C-A3C5-393A0AE6C3E8Q33751411-7BD42713-C513-4D37-9AB3-037C029102E6Q33751838-5362D58A-C7DE-4CB6-8264-D73576E8BCFCQ33754371-57E43FCE-E48F-476F-B2E8-D33FEDC4EEEFQ33762293-23F52DED-F960-4C18-A4F8-35AE478827A3Q33768705-2CAAEB43-ADB9-4289-963E-E5862C268579Q33793546-823C5091-FBD7-41B0-926B-F11E79B91F3CQ33857658-545FE4C6-1F20-4BAB-BC63-1ABF4A29E101Q33877222-C256A229-7341-4BE9-A89F-564121887470Q33909453-61B5CBCC-5D74-427C-A5B8-584D3EC0103AQ33999899-A0FAC1E1-B3A0-41AC-B58F-4F71CEEE3A3CQ34001701-CA0E754F-DE20-49BB-B3D6-18037B0CF174Q34009446-EC490D6A-5574-4B4B-ABD0-D240C90612ADQ34121516-FE6ED0F9-88C8-4643-99F9-8E9F28283E36Q34543565-81CF2191-B3D0-4385-A14D-7058815F9588Q34594241-A2B7A40C-809E-4F85-B97B-7E87DA13486CQ34721109-F5998115-AE02-4C7C-8E2E-BBB6714DF012Q35115708-116EF5DF-7FD9-45AA-AE26-D397957B7EF7Q35118828-BAEB1886-C1DC-43E9-9BB9-FDBA756C3B36Q35386000-8BC7D602-BEA6-4547-9D1E-9B8D022A264BQ35424332-91201722-E5B8-4F63-B04B-1E102622836CQ35431176-44D60EA1-F375-421A-BE47-2896A2D9BE8AQ35434901-285D11BD-8C1C-43B9-9893-BA8F3DDF954EQ35447692-BD72C2DD-F0FF-4EFC-8E47-93960AE2454EQ35514947-1E82F19B-5599-4368-A3E9-ECE197C328A9Q35547271-79A83BF7-D3E7-444A-9BF8-04A486E48796Q35773483-158FEF82-313C-4AEF-8B77-BE6534ADC0F7Q35913526-1A633E8C-75AD-4C4F-B049-F6F35403929CQ36313815-4739213A-63C5-43A1-AA53-EE61D3108699Q36350251-11FD53BF-AFC2-4025-B7DA-8B96A357E615Q36364342-3B772C2B-AF5D-41D6-A655-1E07813B7213Q36366474-E17FABE3-B060-4D9F-BAB9-80E4482641DFQ36973165-8B8979B5-F3E9-45CF-A93D-98E6D2DD5856Q37335906-802C4381-5018-4C14-B5AA-E65C9F7F9A8EQ37337879-93E276A1-C7EF-4CDC-9E85-7D28D601F020Q37438897-CDD5E615-D112-49B0-9745-C4E973E895DBQ37562226-936D24F2-94B2-4932-AB3A-73EA36A5F502Q39517451-B5B5D148-2509-49E5-839B-3CE6CD3561A3
P2860
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Monoclonal antibodies to Crypt ...... intravenous infection in mice.
@ast
Monoclonal antibodies to Crypt ...... intravenous infection in mice.
@en
type
label
Monoclonal antibodies to Crypt ...... intravenous infection in mice.
@ast
Monoclonal antibodies to Crypt ...... intravenous infection in mice.
@en
prefLabel
Monoclonal antibodies to Crypt ...... intravenous infection in mice.
@ast
Monoclonal antibodies to Crypt ...... intravenous infection in mice.
@en
P2093
P2860
P1476
Monoclonal antibodies to Crypt ...... intravenous infection in mice.
@en
P2093
A Casadevall
J Mukherjee
M D Scharff
S Mukherjee
P2860
P304
P407
P577
1994-03-01T00:00:00Z